Plc., JSP Industrial Pharmaceutical Factory Countdown to Start Second Production Line in Dec The latest progress was 80% after opening, preparing to enter the drug business at full capacity. Increase production capacity to 2 million vials per month from current 700,000 vials per month next year, operating at full capacity to support overburdened lockouts after drug trend escalates from COVID period to market shortage. Next year’s revenue is expected to grow 2-3 times and he is ready to see the opportunity that the drug can still grow a lot, the current reason why 90% serve domestic customers. Foreign channels still have high growth potential. Looking at the neighbors, Burma, Laos, Cambodia, they are interesting – they have a similar lifestyle to the Thais and still do not have their own private pharmaceutical factory.
Mr. Sittichai Dangprasert JSP Industrial Pharmaceutical Factory (Thailand) Public Company Limited or JSP, a developer produce and sell Modern medicine, traditional medicine, herbal products and integrated food supplements It was revealed that after JSP had previously invested in expanding production capacity of the second line. Currently, the second production line has progressed by more than 80% and is expected to be ready for commercial operation by the end of this year. After enabling the second line, the JSP performance will increase significantly.
For liquid medicines, JSP currently has a production capacity of 700,000 vials per month. Increased over the previous year with a production capacity of 500,000 bottles per month. However, by the fourth quarter of 2022, the production capacity will increase to 1 million bottles per month. Because the company will ramp up production to 24 hours to support the backlog which is quite large right now. and especially in the month Next December, which will start the second production line, will result in a production capacity of 2 million bottles per month. It is expected that in the coming year, the production capacity will go on fully. As a result, the revenue from this increase is approximately 2-3 times compared to the present.
“The best-selling potion is medicine for children Because after the end of COVID Children are back to school as usual. Causing a lot of discomfort to the children because if a child has a cold, they will catch it easily. As a result, the liquid drug is in short supply. The drug trend continues to grow. We have IPOs during the COVID-19 outbreak, so our liquid drugs are selling better. Going public also makes customers believe in us more. more orders coming. There are now enough block bearings. But before our capacity was already at full capacity. After getting the financing from the IPO, we have the capital to expand the production capacity. It took us 1 year to build the factory, and we will be ready to operate line 2 this December,” Sittichai said.
Mr. Sitthichai said that in the liquid medicine market, the growth opportunity is still quite high because currently 90% is in the domestic market. The export market is still only 10%, so there’s plenty of room for growth. This year, AEC Group customers have started to come back. because many countries have started to open their cities. In addition, in the AEC group, the preference for drugs is similar to Thailand, including Myanmar, Laos and Cambodia without private pharmaceutical factories. It is our opportunity to expand into these countries.
